[ad_1]
[메디게이트뉴스 박도영 기자] The COVID-19 vaccine developed by the University of Oxford and AstraZeneca in the UK was approved for urgent supply and the first dose was shipped on the 30th so that vaccines can start early in the new year.
AstraZeneca announced on the 30th that the UK Medicines and Healthcare Products Regulatory Authority (MHRA) has decided to approve the emergency use of Corona 19 AZD1222 vaccine for the active vaccination of people over 18 years of age.
Based on approval, it is recommended to administer the vaccine twice at 4-12 week intervals. This therapy has been shown to be safe and effective in preventing symptomatic Corona 19 in clinical trials, and there were no serious cases or hospitalizations within 14 days of the second administration.
AstraZeneca aims to supply a total of 100 million doses in the first quarter of 2021 as part of an agreement with the British government.
“Today is an important day for millions of people in the UK to have access to a new vaccine,” said Pascal Soriot, CEO of AstraZeneca. AstraZeneca is provided without any benefit. Thanks to AstraZeneca and colleagues from the University of Oxford, the UK government and tens of thousands of trial participants. “
“This is a time to celebrate Britain’s innovation,” said UK Health Minister Matt Hancock. “This vaccine will help protect many people from this terrible disease in some of the poorest regions of the world at an affordable cost.” It is a hopeful moment, but it is also very important that everyone continues to play their role in preventing infections ”.
MHRA’s decision was made on the basis of independent advice from the Pharmaceuticals Committee after reviewing data from clinical trials that included interim analysis from a phase 3 program led by the University of Oxford. The data was also published in The Lance on December 8.
Additional vaccine safety and efficacy data will continue to accumulate through ongoing clinical trials.
Additionally, in cooperation with global partners, it continues to develop a vaccine production capacity of up to 3 billion doses worldwide by 2021, pending regulatory approval. Vaccines can be stored, transported and handled under general refrigerated conditions (2-8 degrees Celsius) for at least 6 months and can be administered in existing medical settings.
AstraZeneca is expected to be approved in the US and Europe in turn after approval in the UK. However, the European Medicines Agency (EMA) said on the day that AstraZeneca has not yet applied for emergency use approval from the EU, so approval in January next year may not be possible.
The Korean government has signed a contract to purchase 20 million doses of the AstraZeneca vaccine and has announced plans to introduce it from February to March next year.
